275 related articles for article (PubMed ID: 17022858)
21. Patient acceptability of a new 3.0 ml pre-filled insulin pen.
D'Eliseo P; Blaauw J; Milicević Z; Wyatt J; Ignaut DA; Malone JK
Curr Med Res Opin; 2000; 16(2):125-33. PubMed ID: 10893656
[TBL] [Abstract][Full Text] [Related]
22. The redesigned follitropin alfa pen injector: results of the patient and nurse human factors usability testing.
Schertz JC; Saunders H; Hecker C; Lang B; Arriagada P
Expert Opin Drug Deliv; 2011 Sep; 8(9):1111-20. PubMed ID: 21843107
[TBL] [Abstract][Full Text] [Related]
23. An open, randomized single-centre study to compare the efficacy and convenience of follitropin beta administered by a pen device with follitropin alpha administered by a conventional syringe in women undergoing ovarian stimulation for IVF/ICSI.
Platteau P; Laurent E; Albano C; Osmanagaoglu K; Vernaeve V; Tournaye H; Camus M; Van Steirteghem A; Devroey P
Hum Reprod; 2003 Jun; 18(6):1200-4. PubMed ID: 12773446
[TBL] [Abstract][Full Text] [Related]
24. The redesigned follitropin α pen injector for infertility treatment.
Christen M; Schertz JC; Arriagada P; Keitel J; Müller H
Expert Opin Drug Deliv; 2011 Jun; 8(6):833-9. PubMed ID: 21548843
[TBL] [Abstract][Full Text] [Related]
25. Safety and efficacy of Ovaleap® (recombinant human follicle-stimulating hormone) for up to 3 cycles in infertile women using assisted reproductive technology: a phase 3 open-label follow-up to Main Study.
Strowitzki T; Kuczynski W; Mueller A; Bias P
Reprod Biol Endocrinol; 2016 Jun; 14(1):31. PubMed ID: 27287439
[TBL] [Abstract][Full Text] [Related]
26. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus.
Korytkowski M; Bell D; Jacobsen C; Suwannasari R;
Clin Ther; 2003 Nov; 25(11):2836-48. PubMed ID: 14693308
[TBL] [Abstract][Full Text] [Related]
27. A redesigned follitropin alfa pen injector for infertility: results of a market research study.
Abbotts C; Salgado-Braga C; Audibert-Gros C
Patient Prefer Adherence; 2011; 5():315-31. PubMed ID: 21792303
[TBL] [Abstract][Full Text] [Related]
28. Comparison of follitropin-beta administered by a pen device with conventional syringe in an ART programme - a retrospective study.
Rama Raju GA; Suryanarayana K; Jaya Prakash G; Murali Krishna K
J Clin Pharm Ther; 2008 Aug; 33(4):401-7. PubMed ID: 18613858
[TBL] [Abstract][Full Text] [Related]
29. Healthcare professional and patient assessment of a new prefilled insulin pen versus two widely available prefilled insulin pens for ease of use, teaching and learning.
Nadeau DA; Campos C; Niemeyer M; Bailey T
Curr Med Res Opin; 2012 Jan; 28(1):3-13. PubMed ID: 22114905
[TBL] [Abstract][Full Text] [Related]
30. Follitropin-alpha (Gonal-F) versus follitropin-beta (Puregon) in controlled ovarian hyperstimulation for in vitro fertilization: is there any difference?
Orvieto R; Nahum R; Rabinson J; Ashkenazi J; Anteby EY; Meltcer S
Fertil Steril; 2009 Apr; 91(4 Suppl):1522-5. PubMed ID: 18851846
[TBL] [Abstract][Full Text] [Related]
31. Outcomes of new quality standards of follitropin alfa on ovarian stimulation: meta-analysis of previous studies.
Saz-Parkinson Z; López-Cuadrado T; Bouza C; Amate JM
BioDrugs; 2009; 23(1):37-42. PubMed ID: 19344190
[TBL] [Abstract][Full Text] [Related]
32. Use of a prefilled insulin syringe (Novolin Prefilled) by patients with diabetes.
Plevin S; Sadur C
Clin Ther; 1993; 15(2):423-31. PubMed ID: 8519048
[TBL] [Abstract][Full Text] [Related]
33. Acceptability and safety of a new 3.0 ml re-usable insulin pen (HumaPen) in clinical use.
Martin JM; Llewelyn JA; Ristic S; Bates PC
Diabetes Nutr Metab; 1999 Oct; 12(5):306-9. PubMed ID: 10741343
[TBL] [Abstract][Full Text] [Related]
34. Single-arm, observational study of the ease of use of a redesigned pen device to deliver recombinant human follicle-stimulating hormone (follitropin alfa) for assisted reproductive technology treatment.
Illingworth PJ; Lahoud R; Quinn F; Chidwick K; Wilkinson C; Sacks G
Patient Prefer Adherence; 2014; 8():813-26. PubMed ID: 24940048
[TBL] [Abstract][Full Text] [Related]
35. Short coasting of 1 or 2 days by withholding both gonadotropins and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome.
Moon HS; Joo BS; Moon SE; Lee SK; Kim KS; Koo JS
Fertil Steril; 2008 Dec; 90(6):2172-8. PubMed ID: 18439601
[TBL] [Abstract][Full Text] [Related]
36. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R
Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542
[TBL] [Abstract][Full Text] [Related]
37. Functionality and acceptability of a new electronic insulin injection pen with a memory feature.
Venekamp WJ; Kerr L; Dowsett SA; Johnson PA; Wimberley D; McKenzie C; Malone J; Milicevic Z
Curr Med Res Opin; 2006 Feb; 22(2):315-25. PubMed ID: 16466603
[TBL] [Abstract][Full Text] [Related]
38. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data.
Lee WC; Balu S; Cobden D; Joshi AV; Pashos CL
Clin Ther; 2006 Oct; 28(10):1712-25; discussion 1710-1. PubMed ID: 17157128
[TBL] [Abstract][Full Text] [Related]
39. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
[TBL] [Abstract][Full Text] [Related]
40. Lutropin alfa: new preparation. Combined with follitropin for follicular development: no better than menotropin.
Prescrire Int; 2003 Jun; 12(65):91-2. PubMed ID: 12825571
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
